Controversies in Oncology: Mast Cell Tumors
1.0 CE Credit Hour / Craig Clifford, DVM, DACVIM
Craig Clifford
Medical Oncologist
BluePearl Malvern
Dr. Craig Clifford graduated from Mississippi State University College of Veterinary Medicine and received an MS in Animal Science /Virology from the University of Delaware. After completing an internship and a medical oncology residency at the University of Pennsylvania, he became a diplomate of the American College of Veterinary Internal Medicine (Oncology) in 2003. He is a medical oncologist at BluePearl Malvern.
He is active in clinical research within a referral setting and serves as an advisory board member with industry and non-profit foundations. He has authored/co-authored over 70 papers and book chapters and is a frequent lecturer at major veterinary meetings in the USA and abroad.
Dr. Clifford is a member of the Mars Veterinary Health Oncology Advisory Board, has served on many VCS and ACVIM committees, is a member of the Oncology Pathology Working Group, and was an Examiner for the Australian Scientist’s Oncology Specialty Exam.
Overview:
This lecture will discuss the use of cytologic grading for mast cell tumors and which cases are best or assessment and treatment with the newly approved drug Stelfonta with an emphasis on the data behind the drug and where we see it being used in practice.
Learning Objectives:
- Cytologic grading is helpful for surgical planning
- Unless a tumor is a high grade, multiple mast cell tumors carry a similar prognosis as solitary tumors.
- Subcutaneous MCTs, as a general rule, carry a better prognosis.
This course is RACE-approved for 1.0 continuing education credits hours in jurisdictions that accept RACE-approval.
